Lixia Diao

23.6k citations

137 papers · 7.6k indexed · 2 hit papers · h-index 46

Molecular Biology top 1%
Oncology top 0.5%
Cancer Research top 0.5%
Immunology top 2%
Pulmonary and Respiratory Medicine top 2%

Co-authors: Leng Han Jing Wang Lauren A. Byers John V. Heymach Ignacio I. Wistuba Don L. Gibbons Gordon B. Mills Youqiong Ye
Topics: RNA modifications and cancer (27 papers)Cancer-related molecular mechanisms research (20 papers)Cancer Immunotherapy and Biomarkers (17 papers)
Cited by: Cancer Research Oncology Immunology
Journals: Proceedings of the National Academy of Sciences Nucleic Acids Research Journal of Clinical Investigation
Partner nations: United States China Netherlands

In The Last Decade

Lixia Diao

134 papers receiving 7.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer

2019 616 citations Triparna Sen, B. Leticia Rodriguez et al. Cancer Discovery profile →
Epithelial–Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma

2016 349 citations Yanyan Lou, Lixia Diao et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Lixia Diao

Since Specialization

Citations

This map shows the geographic impact of Lixia Diao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lixia Diao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lixia Diao more than expected).

Fields of papers citing papers by Lixia Diao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lixia Diao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lixia Diao. The network helps show where Lixia Diao may publish in the future.

Co-authorship network of co-authors of Lixia Diao

This figure shows the co-authorship network connecting the top 25 collaborators of Lixia Diao. A scholar is included among the top collaborators of Lixia Diao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lixia Diao. Lixia Diao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The pharmacogenomic and immune landscape of snoRNAs in human cancers 2024 ·Cancer Letters ·(unknown),Chengxuan Chen,Yuan Liu,Mei Luo,H. J. Yang,Yamei Chen,(unknown),Liuqing Yang,Chunru Lin,Lixia Diao,Leng Han	1
2	Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC 2021 ·Cancer Research ·Jessica Konen,B. Leticia Rodriguez,(unknown),Joshua K. Ochieng,Laura Gibson,Lixia Diao,Natalie W. Fowlkes,Jared J. Fradette,David H. Peng,Robert J. Cardnell,Jeffrey J. Kovacs,Jing Wang,Lauren A. Byers,Don L. Gibbons	24
3	Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy 2021 ·JNCI Journal of the National Cancer Institute ·Ying Jing,Yongchang Zhang,Jing Wang,Kunyan Li,Xue Chen,Jianfu Heng,Qian Gao,Youqiong Ye,Zhao Zhang,Yaoming Liu,Yanyan Lou,Steven H. Lin,Lixia Diao,Hong Liu,Xiang Chen,Gordon B. Mills,Leng Han	75
4	AXL Inhibition Induces DNA Damage and Replication Stress in Non–Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors 2020 ·Molecular Cancer Research ·Kavya Ramkumar,C. Allison Stewart,Kasey R. Cargill,Carminia Maria Della Corte,Qi Wang,Li Shen,Lixia Diao,Robert J. Cardnell,David H. Peng,B. Leticia Rodriguez,You-Hong Fan,John V. Heymach,(unknown),Carl M. Gay,Don L. Gibbons,Lauren A. Byers	38
5	Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancerbreakdown → 2019 ·Cancer Discovery ·Triparna Sen,B. Leticia Rodriguez,Limo Chen,Carminia Maria Della Corte,Naoto Morikawa,Junya Fujimoto,Sandra Cristea,Thuyen Nguyen,Lixia Diao,Lerong Li,You-Hong Fan,Yongbin Yang,Jing Wang,Bonnie S. Glisson,Ignacio I. Wistuba,Julien Sage,John V. Heymach,Don L. Gibbons,Lauren A. Byers	616
6	Sex specific function of epithelial STAT3 signaling in pathogenesis of K-ras mutant lung cancer 2018 ·Nature Communications ·Mauricio S. Caetano,Maya Hassane,(unknown),(unknown),Amber M. Cumpian,(unknown),(unknown),Huiyuan Zhang,Shanshan Deng,Lixia Diao,Jing Wang,Scott E. Evans,Carmen Behrens,Ignacio I. Wistuba,(unknown),Lin Huang,Laura P. Stabile,Stephanie S. Watowich,Humam Kadara,Seyed Javad Moghaddam	51
7	Poly ADP‐ribose polymerase‐1 as a potential therapeutic target in Merkel cell carcinoma 2018 ·Head & Neck ·Renata Ferrarotto,Robert J. Cardnell,Shirley Y. Su,Lixia Diao,Agda Karina Eterovic,Víctor G. Prieto,(unknown),Jing Wang,Merrill S. Kies,Bonnie S. Glisson,Lauren A. Byers,Diana Bell	9
8	Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer 2017 ·Clinical Cancer Research ·Triparna Sen,Pan Tong,Lixia Diao,Lerong Li,You-Hong Fan,(unknown),John V. Heymach,Jing Wang,Lauren A. Byers	101
9	AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers 2016 ·Molecular Cancer Research ·Kavitha Balaji,Smruthi Vijayaraghavan,Lixia Diao,Pan Tong,You-Hong Fan,Jason P.W. Carey,Tuyen Bui,(unknown),John V. Heymach,Kelly K. Hunt,Jing Wang,Lauren A. Byers,Khandan Keyomarsi	70
10	Hsp90 Inhibitor Ganetespib Sensitizes Non–Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation 2016 ·Clinical Cancer Research ·Yifan Wang,Hui Liu,Lixia Diao,(unknown),Jianhu Zhang,Yawei Qiao,Jing Wang,David A. Proia,Ramesh Tailor,Ritsuko Komaki,Steven H. Lin	27
11	Epithelial–Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinomabreakdown → 2016 ·Clinical Cancer Research ·Yanyan Lou,Lixia Diao,Edwin R. Parra,Warren L. Denning,Limo Chen,You Hong Fan,Lauren A. Byers,Jing Wang,Vassiliki A. Papadimitrakopoulou,Carmen Behrens,Jaime Canales Rodriguez,Patrick Hwu,Ignacio I. Wistuba,John V. Heymach,Don L. Gibbons	349
12	Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer 2016 ·Clinical Cancer Research ·Heath D. Skinner,Uma Giri,Liang Yang,Sang Hyeok Woo,Michael D. Story,Curtis R. Pickering,Lauren A. Byers,Michelle D. Williams,Adel K. El‐Naggar,Jing Wang,Lixia Diao,Li Shen,You Hong Fan,David Molkentine,Beth M. Beadle,Raymond E. Meyn,Jeffrey N. Myers,John V. Heymach	55
13	An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2 2015 ·Clinical Cancer Research ·Robert J. Cardnell,Carmen Behrens,Lixia Diao,You-Hong Fan,Ximing Tang,Pan Tong,John D. Minna,Gordon B. Mills,John V. Heymach,Ignacio I. Wistuba,Jing Wang,Lauren A. Byers	37
14	TANRIC: An Interactive Open Platform to Explore the Function of lncRNAs in Cancer 2015 ·Cancer Research ·Jun Li,Leng Han,Paul Roebuck,Lixia Diao,Lingxiang Liu,Yuan Yuan,John N. Weinstein,Han Liang	407
15	KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib 2015 ·Clinical Cancer Research ·Monique B. Nilsson,Uma Giri,Jayanthi Gudikote,Ximing Tang,Wei Lü,Hai T. Tran,You-Hong Fan,Andrew B. Koo,Lixia Diao,Pan Tong,Jing Wang,Roy S. Herbst,Bruce E. Johnson,Andy Ryan,Alan Webster,Philip Rowe,Ignacio I. Wistuba,John V. Heymach	10
16	Epithelial–Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor–Mediated Apoptosis in Non–Small Cell Lung Cancer 2015 ·Clinical Cancer Research ·Renata Ferrarotto,(unknown),Suk Young Yoo,Pan Tong,Uma Giri,Shaohua Peng,John D. Minna,Luc Girard,Yuehong Wang,Liguang Wang,Lerong Li,Lixia Diao,David H. Peng,Don L. Gibbons,Bonnie S. Glisson,John V. Heymach,Jing Wang,Lauren A. Byers,Faye M. Johnson	40
17	A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma 2014 ·Molecular Cancer Therapeutics ·Tuhina Mazumdar,Lauren A. Byers,Patrick Kwok Shing Ng,Gordon B. Mills,Shaohua Peng,Lixia Diao,You-Hong Fan,Katherine Stemke‐Hale,John V. Heymach,Jeffrey N. Myers,Bonnie S. Glisson,Faye M. Johnson	66
18	Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer 2013 ·Clinical Cancer Research ·Robert J. Cardnell,Ying Feng,Lixia Diao,You-Hong Fan,(unknown),Jing Wang,Yuqiao Shen,Gordon B. Mills,John D. Minna,John V. Heymach,Lauren A. Byers	131
19	Bisphosphorylated PEA-15 Sensitizes Ovarian Cancer Cells to Paclitaxel by Impairing the Microtubule-Destabilizing Effect of SCLIP 2013 ·Molecular Cancer Therapeutics ·Xuemei Xie,(unknown),(unknown),(unknown),Lixia Diao,Keith Baggerly,Gabriel N. Hortobágyi,Naoto T. Ueno	14
20	Activation of β-Catenin Signaling in Androgen Receptor–Negative Prostate Cancer Cells 2012 ·Clinical Cancer Research ·Xinhai Wan,Jie Liu,(unknown),Vassiliki Tzelepi,Jun Yang,Michael W. Starbuck,Lixia Diao,Jing Wang,Eleni Efstathiou,Elba S. Vázquez,Patricia Troncoso,Sankar N. Maity,Nora M. Navone	61

About Lixia Diao

Lixia Diao is a scholar working on Cancer Research, Oncology and Molecular Biology, having authored 137 papers that have together received 7.6k indexed citations. Recurring topics across this work include RNA modifications and cancer (27 papers), Cancer-related molecular mechanisms research (20 papers) and Cancer Immunotherapy and Biomarkers (17 papers). The work is most often cited by research in Cancer Research (2.3k citations), Oncology (2.8k citations) and Immunology (1.4k citations). Lixia Diao has collaborated with scholars based in United States, China and Netherlands. Frequent co-authors include Leng Han, Jing Wang, Lauren A. Byers, John V. Heymach, Ignacio I. Wistuba, Don L. Gibbons, Gordon B. Mills, Youqiong Ye, John N. Weinstein and Zhao Zhang. Their work appears in journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Clinical Investigation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact